Fig. 4From: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)The overall mean percentage of patients with 100% reduction in monthly MHDs across Months 1–6 is shown for patients with LFEM and HFEM receiving placebo, 120-mg, or 240-mg of galcanezumab in the upper row. The monthly percentage of patients with 100% reduction in MHDs is shown in the bottom row for patients with LFEM and with HFEM. ***p ≤ .001, **p ≤ .01, *p ≤ .05 vs placeboBack to article page